Daiichi Sankyo is headquartered in Parsippany-Troy Hills, US
Report incorrect company information
Key People/Management at Daiichi Sankyo
George Nakayama
Representative Director, Chairman and CEO
Sunao Manabe
Representative Director, Member of the Board, President and COO
Toshiaki Sai
Representative Director, Member of the Board, Executive Vice President and CFO
Katsumi Fujimoto
Member of the Board, Senior Executive Officer
Noritaka Uji
Member of the Board (Outside)
Hideyuki Haruyama
Member of the Audit and Supervisory Board
Report incorrect company information
Daiichi Sankyo Office Locations
Daiichi Sankyo has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
2 Hilton Ct
Report incorrect company information
Daiichi Sankyo Online and Social Media Presence
242 Twitter followers
Daiichi Sankyo has 242 Twitter Followers. The number of followers has increased 2.5% month over month and increased 9.2% quarter over quarter
200 Facebook likes
Daiichi Sankyo has 200 Facebook Likes. The number of likes has increased 5.8% month over month and increased 11.5% quarter over quarter
Report incorrect company information
Daiichi Sankyo News and Updates
August 09, 2018
SOHM, Inc. Subsidiary Daiichi Sankyo Group Files Its Acute Myeloid Leukemia (AML) Treatment Quizartinib in the US; the FDA Awarded Breakthrough Status for The Drug
Chino Hills, CA - (NewMediaWire) - August 9, 2018 - SOHM, Inc. (PINKSHEETS: SHMN), a globally-known generic pharmaceutical manufacturer, announced that its subsidiary Daiichi Sankyo Group filed its acute myeloid leukemia (AML) treatment Quizartinib in the US; the FDA awarded breakthrough status…
April 01, 2018
Daiichi Sankyo partners with Crohn’s & Colitis Foundation to draw attention to iron deficiency
A new disease awareness campaign from Daiichi Sankyo highlights iron deficits common in patients with Crohn’s disease and ulcerative colitis. Daiichi is working with the Crohn’s & Colitis Foundation on the campaign, Called “Get Iron Informed,” to encourage patients with inflammatory bowel diseas…
August 04, 2017
FiercePharmaAsia—GSK’s neurology R&D hub, Pfizer-Astellas’ aborted Xtandi mission, Daiichi Sankyo’s Benicar settlement
GlaxoSmithKline will soon close its global neuroscience R&D hub located in Shanghai, Pfizer and Astellas have decided to discontinue research into Xtandi's usage in breast cancer, Daiichi Sankyo is offering $300 million to settle about 2,300 lawsuits around Benicar and other news items from Asia…
Report incorrect company information
Daiichi Sankyo Company Life and Culture
Report incorrect company information